News

Adding immunotherapy to standard chemotherapy extends quality of life for patients with advanced endometrial cancer
A study co-led by UCLA Health Jonsson Comprehensive Cancer Center investigators found that combining the immunotherapy drug ...
Mirage News10h
Immunotherapy Boosts Life Quality in Endometrial Cancer
A study co-led by UCLA Health Jonsson Comprehensive Cancer Center investigators found that combining the immunotherapy drug dostarlimab with ...
Why some skin cancers defy immunotherapy—and how to fight back
A study has revealed why some patients don't respond to immune checkpoint blockade (ICB) therapy for solid cancer tumors and ...
SurvivorNet on MSN11h
Adding Immunotherapy To The Treatment Plan Helps Keep Gastric Cancer Under Control Longer: Breaking Down The Practice-Changing New Data
Data shows adding durvalumab (Imfinzi) to the standard chemotherapy combination known as FLOT before and after surgery kept ...
News-Medical.Net on MSN14h
New combination treatment offers hope for immune checkpoint blockade resistant skin cancers
A study has revealed why some patients don't respond to immune checkpoint blockade (ICB) therapy for solid cancer tumors and ...
The Manila Times14h
Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting
Context Therapeutics Inc. ("Context” or "Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T ...
Le Lézard7h
ImmuneOncia Announces Interim Results from Phase 1b Clinical Trial of Next-Generation CD47 Antibody 'IMC-002' at ASCO 2025
ImmuneOncia Therapeutics, Inc. (CEO Heung-Tae Kim) announced interim results today from the ongoing Phase 1b clinical trial of its next-generation CD47-targeting antibody, IMC-002, in combination with ...